Free Trial

Vaxcyte (PCVX) Competitors

$70.27
+0.06 (+0.09%)
(As of 05/31/2024 ET)

PCVX vs. FMTX, SRRK, EDIT, ADVM, SGMO, ARGX, BNTX, NBIX, TECH, and QGEN

Should you be buying Vaxcyte stock or one of its competitors? The main competitors of Vaxcyte include Forma Therapeutics (FMTX), Scholar Rock (SRRK), Editas Medicine (EDIT), Adverum Biotechnologies (ADVM), Sangamo Therapeutics (SGMO), argenx (ARGX), BioNTech (BNTX), Neurocrine Biosciences (NBIX), Bio-Techne (TECH), and Qiagen (QGEN). These companies are all part of the "biological products, except diagnostic" industry.

Vaxcyte vs.

Vaxcyte (NASDAQ:PCVX) and Forma Therapeutics (NASDAQ:FMTX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, community ranking, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Vaxcyte has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Forma Therapeutics has a beta of -0.94, indicating that its stock price is 194% less volatile than the S&P 500.

In the previous week, Vaxcyte had 8 more articles in the media than Forma Therapeutics. MarketBeat recorded 8 mentions for Vaxcyte and 0 mentions for Forma Therapeutics. Vaxcyte's average media sentiment score of 1.42 beat Forma Therapeutics' score of 0.00 indicating that Vaxcyte is being referred to more favorably in the media.

Company Overall Sentiment
Vaxcyte Positive
Forma Therapeutics Neutral

Vaxcyte's return on equity of -28.83% beat Forma Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
VaxcyteN/A -28.83% -26.89%
Forma Therapeutics N/A -39.68%-35.33%

Forma Therapeutics has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Forma Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VaxcyteN/AN/A-$402.27M-$4.28-16.42
Forma Therapeutics$100.56M9.52-$172.96M-$4.00-5.00

Vaxcyte currently has a consensus price target of $78.50, suggesting a potential upside of 11.71%. Given Vaxcyte's higher possible upside, research analysts clearly believe Vaxcyte is more favorable than Forma Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vaxcyte
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
Forma Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Vaxcyte received 3 more outperform votes than Forma Therapeutics when rated by MarketBeat users. Likewise, 68.75% of users gave Vaxcyte an outperform vote while only 51.72% of users gave Forma Therapeutics an outperform vote.

CompanyUnderperformOutperform
VaxcyteOutperform Votes
33
68.75%
Underperform Votes
15
31.25%
Forma TherapeuticsOutperform Votes
30
51.72%
Underperform Votes
28
48.28%

96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 87.4% of Forma Therapeutics shares are held by institutional investors. 3.1% of Vaxcyte shares are held by insiders. Comparatively, 5.8% of Forma Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Vaxcyte beats Forma Therapeutics on 10 of the 15 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PCVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PCVX vs. The Competition

MetricVaxcyteBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$7.64B$2.85B$5.12B$7.96B
Dividend YieldN/A2.29%2.75%4.00%
P/E Ratio-16.4212.93127.4515.73
Price / SalesN/A349.752,432.9793.31
Price / CashN/A162.0635.1831.51
Price / Book3.856.315.534.59
Net Income-$402.27M-$45.89M$105.96M$213.90M
7 Day Performance2.20%-2.41%1.14%0.87%
1 Month Performance10.30%-0.45%1.43%3.60%
1 Year Performance39.70%0.78%4.09%7.91%

Vaxcyte Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FMTX
Forma Therapeutics
0 of 5 stars
$20.01
flat
N/A+0.0%$957.54M$100.56M-5.00166
SRRK
Scholar Rock
4.6119 of 5 stars
$9.05
-1.7%
$25.17
+178.1%
+61.3%$721.74M$33.19M-4.33150Gap Down
EDIT
Editas Medicine
3.8014 of 5 stars
$5.08
-0.4%
$13.90
+173.6%
-43.4%$417.78M$78.12M-2.42265Analyst Forecast
Analyst Revision
Positive News
ADVM
Adverum Biotechnologies
4.3415 of 5 stars
$7.90
-1.5%
$29.00
+267.1%
-35.6%$164.00M$3.60M-0.77121Short Interest ↓
Positive News
SGMO
Sangamo Therapeutics
1.3253 of 5 stars
$0.56
-2.1%
$5.67
+907.8%
-49.6%$116.68M$18.76M-0.30405Positive News
ARGX
argenx
3.4519 of 5 stars
$375.18
-0.7%
$520.68
+38.8%
-4.5%$22.30B$1.27B-66.291,148Analyst Forecast
Short Interest ↓
Positive News
BNTX
BioNTech
1.7443 of 5 stars
$92.86
-0.4%
$111.70
+20.3%
-4.3%$22.08B$4.13B185.726,133Analyst Forecast
Short Interest ↓
NBIX
Neurocrine Biosciences
4.7231 of 5 stars
$134.74
+0.1%
$150.85
+12.0%
+51.2%$13.56B$1.89B37.121,400Analyst Forecast
Insider Selling
Positive News
Gap Down
TECH
Bio-Techne
4.0167 of 5 stars
$76.56
-2.6%
$81.00
+5.8%
-5.6%$12.07B$1.14B60.763,050
QGEN
Qiagen
4.0849 of 5 stars
$42.64
+0.1%
$50.95
+19.5%
-7.1%$9.73B$1.97B28.595,967

Related Companies and Tools

This page (NASDAQ:PCVX) was last updated on 6/1/2024 by MarketBeat.com Staff

From Our Partners